Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1403 in Advanced Solid Tumors
NCT03856541Phase 1Completed
- Sponsor
- Hengrui
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-A1403 in solid tumor (advanced stage), sponsored by Hengrui. Primary endpoints: Treatment-related Adverse Events up to 24 months, Dose Limited Toxicity up to 24 months and 1 more. Started Feb 2019; status: completed.
02
Drugs
SHR-A1403
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03856541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856541.